Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.
Baig NA, Taylor RP, Lindorfer MA, Church AK, Laplant BR, Pavey ES, Nowakowski GS, Zent CS. Baig NA, et al. Among authors: zent cs. Leuk Lymphoma. 2012 Nov;53(11):2218-27. doi: 10.3109/10428194.2012.681657. Epub 2012 May 21. Leuk Lymphoma. 2012. PMID: 22475085 Free PMC article.
Anti-CD20 antibody therapy for B-cell lymphomas.
Taylor RP, Lindorfer MA, Zent CS. Taylor RP, et al. Among authors: zent cs. N Engl J Med. 2012 Aug 30;367(9):876-7; author reply 878. doi: 10.1056/NEJMc1207378. N Engl J Med. 2012. PMID: 22931338 Free article. No abstract available.
Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.
Zent CS, Taylor RP, Lindorfer MA, Beum PV, LaPlant B, Wu W, Call TG, Bowen DA, Conte MJ, Frederick LA, Link BK, Blackwell SE, Veeramani S, Baig NA, Viswanatha DS, Weiner GJ, Witzig TE. Zent CS, et al. Am J Hematol. 2014 Jul;89(7):757-65. doi: 10.1002/ajh.23737. Epub 2014 Apr 26. Am J Hematol. 2014. PMID: 24723493 Free PMC article. Clinical Trial.
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.
Oostindie SC, van der Horst HJ, Lindorfer MA, Cook EM, Tupitza JC, Zent CS, Burack R, VanDerMeid KR, Strumane K, Chamuleau MED, Mutis T, de Jong RN, Schuurman J, Breij ECW, Beurskens FJ, Parren PWHI, Taylor RP. Oostindie SC, et al. Among authors: zent cs. Haematologica. 2019 Sep;104(9):1841-1852. doi: 10.3324/haematol.2018.207266. Epub 2019 Feb 21. Haematologica. 2019. PMID: 30792198 Free PMC article.
174 results